{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:43:26Z","timestamp":1791301406449,"version":"4.1.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2005,11,4]],"date-time":"2005-11-04T00:00:00Z","timestamp":1131062400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2005,12]]},"DOI":"10.1007\/s00277-005-0026-8","type":"journal-article","created":{"date-parts":[[2005,11,3]],"date-time":"2005-11-03T14:08:59Z","timestamp":1131026939000},"page":"61-66","source":"Crossref","is-referenced-by-count":124,"title":["Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia"],"prefix":"10.1007","volume":"84","author":[{"given":"Andrea","family":"Kuendgen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Knipp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinna","family":"Strupp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Hildebrandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Steidl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Germing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Haas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Gattermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2005,11,4]]},"reference":[{"key":"26_CR1","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S1044-579X(02)00053-6","volume":"12","author":"SB Baylin","year":"2002","unstructured":"Baylin SB (2002) Mechanisms underlying epigenetically mediated gene silencing in cancer. Semin Cancer Biol 12:331\u2013337","journal-title":"Semin Cancer Biol"},{"key":"26_CR2","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/5047","volume":"21","author":"EE Cameron","year":"1999","unstructured":"Cameron EE, Bachman KE, Myohanen S et al (1999) Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 21:103\u2013107","journal-title":"Nat Genet"},{"key":"26_CR3","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1476-4598-4-22","volume":"4","author":"A Chavez-Blanco","year":"2005","unstructured":"Chavez-Blanco A, Segura-Pacheco B, Perez-Cardenas E et al (2005) Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study. Mol Cancer 4:22","journal-title":"Mol Cancer"},{"key":"26_CR4","first-page":"3671","volume":"96","author":"BD Cheson","year":"2000","unstructured":"Cheson BD, Bennett JM, Kantarjian H et al (2000) Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 96:3671\u20133674","journal-title":"Blood"},{"key":"26_CR5","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","volume":"21","author":"BD Cheson","year":"2003","unstructured":"Cheson BD, Bennett JM, Bloomfield CD et al (2003) Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 21:4642\u20134649","journal-title":"J Clin Oncol"},{"key":"26_CR6","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1097\/00001813-199711000-00007","volume":"8","author":"J Cinatl","year":"1997","unstructured":"Cinatl J Jr, Cinatl J, Driever PH et al (1997) Sodium valproate inhibits in vivo growth of human neuroblastoma cells. Anti-Cancer Drugs 8:958\u2013963","journal-title":"Anti-Cancer Drugs"},{"key":"26_CR7","doi-asserted-by":"crossref","unstructured":"Garcia-Manero G, Kantarjian H, Issa J-P et al (2004) Results of a phase I\/II study of the combination of 5-aza-2\u2032-deoxycytidine (DAC) and valproic acid (VPA) in patients with leukaemia. Blood 104(Suppl 1):abstract 263","DOI":"10.1182\/blood.V104.11.263.263"},{"key":"26_CR8","doi-asserted-by":"crossref","first-page":"6969","DOI":"10.1093\/emboj\/20.24.6969","volume":"20","author":"M Gottlicher","year":"2001","unstructured":"Gottlicher M, Minucci S, Zhu P et al (2001) Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20:6969\u20136978","journal-title":"EMBO J"},{"key":"26_CR9","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","volume":"89","author":"P Greenberg","year":"1997","unstructured":"Greenberg P, Cox C, LeBeau MM et al (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079\u20132088","journal-title":"Blood"},{"key":"26_CR10","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1182\/blood.V92.1.68.413k23_68_75","volume":"92","author":"E Hellstrom-Lindberg","year":"1998","unstructured":"Hellstrom-Lindberg E, Ahlgren T, Beguin Y et al (1998) Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. Blood 92:68\u201375","journal-title":"Blood"},{"key":"26_CR11","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/561","volume":"19","author":"PL Jones","year":"1998","unstructured":"Jones PL, Veenstra GJ, Wade PA et al (1998) Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet 19:187\u2013191","journal-title":"Nat Genet"},{"key":"26_CR12","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S0145-2126(01)00151-5","volume":"26","author":"R Kawagoe","year":"2002","unstructured":"Kawagoe R, Kawagoe H, Sano K (2002) Valproic acid induces apoptosis in human leukemia cells by stimulating both caspase-dependent and -independent apoptotic signaling pathways. Leuk Res 26:495\u2013502","journal-title":"Leuk Res"},{"key":"26_CR13","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1093\/emboj\/cdg315","volume":"22","author":"OH Kramer","year":"2003","unstructured":"Kramer OH, Zhu P, Ostendorff HP et al (2003) The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2. EMBO J 22:3411\u20133420","journal-title":"EMBO J"},{"key":"26_CR14","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1182\/blood-2003-12-4333","volume":"104","author":"A Kuendgen","year":"2004","unstructured":"Kuendgen A, Strupp C, Aivado M et al (2004) Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. Blood 104:1266\u20131269","journal-title":"Blood"},{"key":"26_CR15","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMoa041668","volume":"352","author":"A List","year":"2005","unstructured":"List A, Kurtin S, Roe DJ et al (2005) Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 352:549\u2013557","journal-title":"N Engl J Med"},{"key":"26_CR16","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2165\/00023210-200216100-00003","volume":"16","author":"W Loscher","year":"2002","unstructured":"Loscher W (2002) Basic pharmacology of valproate: a review after 35\u00a0years of clinical use for the treatment of epilepsy. CNS Drugs 16:669\u2013694","journal-title":"CNS Drugs"},{"key":"26_CR17","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1093\/jnci\/91.15.1288","volume":"91","author":"RX Luo","year":"1999","unstructured":"Luo RX, Dean DC (1999) Chromatin remodeling and transcriptional regulation. J Natl Cancer Inst 91:1288\u20131294","journal-title":"J Natl Cancer Inst"},{"key":"26_CR18","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1093\/jnci\/92.15.1210","volume":"92","author":"PA Marks","year":"2000","unstructured":"Marks PA, Richon VM, Rifkind RA (2000) Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 92:1210\u20131216","journal-title":"J Natl Cancer Inst"},{"key":"26_CR19","doi-asserted-by":"crossref","first-page":"36734","DOI":"10.1074\/jbc.M101287200","volume":"276","author":"CJ Phiel","year":"2001","unstructured":"Phiel CJ, Zhang F, Huang EY et al (2001) Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 276:36734\u201336741","journal-title":"J Biol Chem"},{"key":"26_CR20","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1182\/blood.V94.2.417","volume":"94","author":"RL Redner","year":"1999","unstructured":"Redner RL, Wang J, Liu JM (1999) Chromatin remodeling and leukemia: new therapeutic paradigms. Blood 94:417\u2013428","journal-title":"Blood"},{"key":"26_CR21","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1038\/sj.leu.2403528","volume":"18","author":"RF Schlenk","year":"2004","unstructured":"Schlenk RF, Frohling S, Dohner H et al; AML Study Group Ulm (2004) Phase III study of all-trans retinoic acid in previously untreated patients 61\u00a0years or older with acute myeloid leukemia. Leukemia 18:1798\u20131803","journal-title":"Leukemia"},{"key":"26_CR22","first-page":"2766","volume":"59","author":"J Wang","year":"1999","unstructured":"Wang J, Saunthararajah Y, Redner RL et al (1999) Inhibitors of histone deacetylase relieve ETO-mediated repression and induce differentiation of AML1-ETO leukemia cells. Cancer Res 59:2766\u20132769","journal-title":"Cancer Res"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-005-0026-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-005-0026-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-005-0026-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,19]],"date-time":"2021-07-19T03:32:44Z","timestamp":1626665564000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-005-0026-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,11,4]]},"references-count":22,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2005,12]]}},"alternative-id":["26"],"URL":"https:\/\/doi.org\/10.1007\/s00277-005-0026-8","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,11,4]]}}}